Previously, EGFR mutation-positive NSCLC patients relied ... The CLDN18.2 biomarker is expressed by about 35% of Chinese stomach cancer patients, according to Astellas. The approval was backed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback